Side-by-side · Research reference

SemaglutidevsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified15/53 cited

BPhase 3Reviewed8/39 cited

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Semaglutide

Thymosin α-1

Primary target

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

—

Origin

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

Semaglutide

Thymosin α-1

Standard dose (T2D, Ozempic)

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

—

Standard dose (weight, Wegovy)

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

—

Frequency

Once weekly, same day each week

2× weekly (Mon/Thu typical)

Titration schedule

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

Indefinite for chronic indication

Discontinuation results in weight regain.

6–12 months for chronic indications

Reconstitution

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Sterile water for injection per vial label

Timing

Any time of day, with or without food

No specific time

Half-life

~7 days (168 h)WEGOVY (semaglutide) injection 2021

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Lower / starter dose

—

0.8 mg per injection

04Side Effects & Safety

Parameter

Semaglutide

Thymosin α-1

GI symptoms

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Rare nausea

Injection site reaction

Mild erythema, pruritus

Erythema, mild discomfort

Pancreatitis risk

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

—

Hypoglycemia

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

ContraindicatedWEGOVY (semaglutide) injection 2021

Avoid

Heart rate

Modest ↑ resting HR (~2-4 bpm)

—

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Absolute Contraindications

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Semaglutide

Thymosin α-1

1. Reconstitution / device

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Once weekly, same day. Day can be changed if ≥2 days separate doses.

2× weekly, e.g. Monday + Thursday.

4. Storage

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)

Thymosin α-1

— no documented stacks